埃普奈明治疗复发难治多发性骨髓瘤临床应用指导原则(2024年版)  

Principles for clinical application of aponermin in treatment of relapsed/refractory multiple myeloma (2024 version)

作　　者：中国临床肿瘤学会(CSCO)白血病专家委员会 中国临床肿瘤学会(CSCO)淋巴瘤专家委员会 中国临床肿瘤学会(CSCO)骨髓瘤筹备委员会 马军[2] 陈文明[3] Leukemia Expert Committee of Chinese Society of Clinical Oncology(CSCO);Lymphoma Expert Committee of Chinese Society of Clinical Oncology(CSCO);Myeloma Preparatory Expert Committee of Chinese Society of Clinical Oncology(CSCO);Ma Jun;Chen Wenming(不详;Harbin Institute of Hematology and Oncology,Harbin 150010;Department of Hematology,Beijing Chaoyang Hospital,Capital MedicalUniversity,Beijing 100020)

机构地区：[1]不详 [2]哈尔滨血液病肿瘤研究所,哈尔滨150010 [3]首都医科大学附属北京朝阳医院血液科,北京100020

出　　处：《白血病．淋巴瘤》2024年第2期74-81,共8页Journal of Leukemia & Lymphoma

摘　　要：埃普奈明是重组环化变构的人肿瘤坏死因子相关凋亡诱导配体,通过激活死亡受体4/死亡受体5(DR4/DR5)诱导不依赖p53的细胞凋亡,是全球首个获批上市的DR4/DR5激动剂,用于治疗复发难治多发性骨髓瘤(RRMM)。RRMM患者接受埃普奈明单药或联合用药治疗具有较好的疗效及安全性。鉴于目前我国临床医生缺乏对该药的临床应用经验,中国临床肿瘤学会(CSCO)组织国内专家制定了埃普奈明在RRMM中的临床应用指导原则,旨在为临床医生提供参考。Aponermin is a recombinant circularly permuted tumor necrosis factor-related apoptosis-inducing ligand that induces p53 independent cell apoptosis by activating death receptor 4/death receptor 5(DR4/DR5).It is the first globally approved DR4/DR5 agonist for the treatment of relapsed/refractory multiple myeloma(RRMM).RRMM patients receiving aponermin monotherapy or the combination therapy with other drugs have good efficacy and safety.In view of the lack of experience in clinical use,the Chinese Society of Clinical Oncology(CSCO)has organized experts to formulate the clinical application principles of aponermin in RRMM,aiming to provide a reference for clinicians.

关 键 词：多发性骨髓瘤 埃普奈明 肿瘤坏死因子相关凋亡诱导配体 死亡受体4 死亡受体5 

分 类 号：R733.3[医药卫生—肿瘤]